Targeting specific immune cells to improve treatment for acute myeloid leukemia
Myeloid cell-selective, oligonucleotide-based STAT3 inhibition combined with total marrow and lymphoid irradiation for immunotherapy of acute myeloid leukemia
This study is testing a new way to treat acute myeloid leukemia (AML) by using a special combination of targeted treatments that block a protein called STAT3 along with a type of radiation therapy, to see if it can help improve survival for patients whose cancer hasn't responded to other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10890879 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treat acute myeloid leukemia (AML) by combining targeted oligonucleotide-based inhibitors of the STAT3 protein with a specialized radiation therapy called total marrow and lymphoid irradiation (TMLI). The goal is to enhance the effectiveness of TMLI, which has shown promise in improving survival rates for patients with treatment-refractory AML. By specifically inhibiting STAT3 in myeloid cells, the research aims to reduce the cancer-promoting effects of these cells and improve patient outcomes. Patients may be monitored for their response to this combined treatment strategy over the course of the study.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with treatment-refractory acute myeloid leukemia who are considering allogeneic hematopoietic cell transplantation.
Not a fit: Patients with early-stage acute myeloid leukemia or those who are not candidates for allogeneic hematopoietic cell transplantation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and reduce relapses in patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown that combining targeted therapies with radiation can improve outcomes in cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Kortylewski, Marcin — Beckman Research Institute/city of Hope
- Study coordinator: Kortylewski, Marcin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.